Bellerophon Therapeutics, Inc.
BLPHDelisted Dec 27, 2023- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001600132
Bellerophon Therapeutics, Inc. was delisted on Dec 27, 2023; its insiders filed their last Form 4 on Oct 16, 2023; 22 institutions reported holding it in 13F filings for Q3 2023, worth $506.6K in total; no superinvestor held it.
Holders of 5% or more of BLPH
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Bellerophon Therapeutics, Inc., largest stake first. The change is against the holder's previous filing.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Nelson Michael Aaron | 13G | 5.30%642.8K shares | 0.00 ppfrom 5.30% | Jan 26, 20242 filings | Mar 1, 2024 | SEC |
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
18 Schedule 13D and 13G filings on Bellerophon Therapeutics, Inc., newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Mar 1, 202410:04 AM ET | Nelson Michael Aaron | 13G | 5.30%642.8K shares | 0.00 ppfrom 5.30% | Feb 22, 2024 | SEC |
| Feb 14, 2024 | Tang Capital Partners LP | 13G/AOld format | – | – | – | SEC |
| Feb 14, 2024 | Perceptive Advisors LLC | 13G/AOld format | – | – | – | SEC |
| Jan 26, 20242:31 PM ET | Nelson Michael Aaron | 13G | 5.30%642.8K shares | New | Jan 16, 2024 | SEC |
| Jan 26, 2024 | Lepercq De Neuflize Asset Management LLC | 13GOld format | – | New | – | SEC |
| Oct 18, 2023 | Puissance Life Science Opportunities Fund VI | 13D/AOld format | – | – | – | SEC |
| Oct 17, 2023 | Puissance Life Science Opportunities Fund VI | 13D/AOld format | – | – | – | SEC |
| Jun 9, 2023 | Janus Henderson Group PLC | 13G/AOld format | – | – | – | SEC |
| Jun 8, 2023 | Puissance Life Science Opportunities Fund VI | 13D/AOld format | – | – | – | SEC |
| May 26, 2023 | Janus Henderson Group PLC | 13G/AOld format | – | – | – | SEC |
| May 25, 2023 | Janus Henderson Group PLC | 13GOld format | – | New | – | SEC |
| May 22, 2023 | Puissance Life Science Opportunities Fund VI | 13D/AOld format | – | – | – | SEC |
| Mar 17, 2023 | Tang Capital Partners LP | 13GOld format | – | New | – | SEC |
| Mar 14, 2023 | Perceptive Advisors LLC | 13GOld format | – | New | – | SEC |
| Feb 14, 2022 | New Mountain Investments II, LLC | 13G/AOld format | – | – | – | SEC |
| Apr 28, 2021 | Puissance Life Science Opportunities Fund VI | 13D/AOld format | – | – | – | SEC |
| Feb 12, 2021 | New Mountain Investments II, LLC | 13G/AOld format | – | – | – | SEC |
| Jan 5, 2021 | Sabby Management, LLC | 13G/AOld format | – | – | – | SEC |
Form 144: proposed insider sales
2 notices from officers, directors and other affiliates planning to sell Bellerophon Therapeutics, Inc. shares, newest first.
| Filed (ET) | Seller | Shares to sell | Market value | Planned sale | Broker | Filing |
|---|---|---|---|---|---|---|
| Jun 7, 20238:57 PM ET | Puissance Life Science Opportunities Fund VI10% stockholder | 134.4K | $111.4K | Jun 7, 202310b5-1 | Goldman Sachs & Co. LLC | SEC |
| May 18, 20238:50 PM ET | Puissance Life Science Opportunities Fund VI10% stockholder | 560.0K | $5.30M | May 18, 202310b5-1 | Cowen and Co | SEC |